Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region

Seland, Mette; Holte, Harald; Bjøro, Trine; Schreiner, Thomas; Bollerslev, Jens; Loge, Jon Håvard; Fosså, Sophie D.; Kiserud, Cecilie E.

doi:10.3109/10428194.2015.1036258

Cited by 18 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of CF and fatigue levels found among survivors of BC and NHL in the present study are consistent with previous findings among survivors diagnosed with BC and NHL as older adults [12,25]. Among the CRC survivors, our result supports the finding of Thong and colleagues [26], who demonstrated a high prevalence of fatigue (35%) up to 10 years post-diagnosis in CRC survivors aged mean 70 years at the survey.…”

Section: Discussionsupporting

confidence: 92%

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood

et al. 2019

Self Cite

View full text Add to dashboard Cite

Background: Chronic fatigue (CF) is scarcely explored among young adult cancer survivors (YACSs), and more knowledge is needed to develop targeted interventions for YACSs with CF. The present study aimed to investigate the prevalence of CF and associated factors in YACSs. Also, the change of fatigue with time was explored. Material and methods: The present cross-sectional study is part of a nationwide population based survey of Norwegian survivors of cancer in childhood, adolescence, and young adulthood (The NOR-CAYACS study).YACSs diagnosed at the age of 19-39 years with breast cancer stage III (BC), colorectal cancer (CRC), non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia, or non-metastatic malignant melanoma (MM) were included 5-30 years after diagnosis. Survivors of MM treated with limited surgery were included as a reference group. CF was assessed by the Fatigue Questionnaire. Logistic regression analyses were performed to identify factors associated with CF. Results: In total, 1488 survivors completed the questionnaire (a response rate of 42%), of which 1088 were eligible for the present study. Overall, 25% reported CF. CF was significantly more prevalent among survivors of BC (29%) (p < .001), CRC (29%) (p ¼ .001) and NHL (27%) (p ¼ .003) than among survivors of MM (15%). CF was associated with systemic treatment combined with surgery and/or radiotherapy (p ¼ .018), comorbidity (p ¼ .038), pain (p ¼ .002), numbness in hands/feet (p ¼ .046), and depressive symptoms (p < .001) in the multivariable model. Among survivors with CF, 60% reported that they had been tired since cancer treatment, and among these, 65% reported worsening or no change of fatigue with time. Conclusion: One of four YACSs reported CF 15 years from diagnosis (mean). CF was associated with several possibly treatable factors. Health professionals involved in the follow-up of YACSs should have knowledge of CF and approaches to manage it.

show abstract

Section: Discussionsupporting

confidence: 92%

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…Most published studies have focused on health‐related quality of life using instruments that occasionally include item(s) on fatigue. Of these, only 1 studied chronic fatigue and its relation with hormone dysfunction as a result of treatment . In a series of 98 Norwegian NHL survivors who received radiotherapy to the head‐and‐neck region (median age, 61.3 years; median follow‐up, 16.4 years), the authors observed that 29% of survivors expressed chronic fatigue based on the Fatigue Questionnaire (FQ) assessment, independent of sex, age, and treatment.…”

Section: Discussionmentioning

confidence: 99%

“…Of these, only 1 studied chronic fatigue and its relation with hormone dysfunction as a result of treatment. 21 In a series of 98 Norwegian NHL survivors who received radiotherapy to the head-and-neck region (median age, 61.3 years; median follow-up, 16.4 years), the authors observed that 29% of survivors expressed chronic fatigue based on the Fatigue Questionnaire (FQ) assessment, independent of sex, age, and treatment. In multivariate analysis, using the Hospital Anxiety and Depression questionnaire to assess anxiety or depression, chronic fatigue was dependent on anxiety/depression (P < .001) and on hormone dysfunction (P = .02), in agreement with our results.…”

Section: Discussionmentioning

confidence: 99%

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

Mounier¹,

Anthony

Busson³

et al. 2019

Cancer

View full text Add to dashboard Cite

Background Long‐term survivors of non‐Hodgkin lymphoma (NHL) must cope with treatment complications and late toxicities that affect their health‐related quality of life. Little is known about the risk‐to‐benefit ratio of new agents like rituximab. The impact of treatment regimens and health disorders on long‐term fatigue levels was investigated in a cross‐sectional study. Methods Two self‐administered questionnaires, the 20‐item Multidimensional Fatigue Inventory (MFI‐20) and a Life Situation Questionnaire, were mailed in 2015 to NHL survivors enrolled onto 12 successive clinical studies (1993‐2010) conducted by the Lymphoma Study Association. Private addresses were obtained for 3317 survivors, of whom 1671 (50%) returned the questionnaires. Severe fatigue was defined as MFI‐20 scores ≥60 on dimension scales scored from 0 to 100. Linear regression models were used to assess factors that were linked to increased fatigue levels. Results The study population included 906 men and 765 women, and the median age was 64 years (age range, 24‐95 years). Overall, 811 survivors had received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP)‐like chemotherapy, 518 had received high‐dose CHOP, and 342 had undergone upfront autologous stem cell transplantation; 829 survivors also had received rituximab. In total, 1100 survivors (66%) reported 1 or more late health disorders. Severe fatigue was reported by 602 survivors (37%). Increased fatigue levels were associated (P < .001) with increased age, obesity, and the presence of health disorders, but not with initial treatment or rituximab. Conclusions The survey confirms that high proportions long‐term NHL survivors have severe fatigue. The results suggest that initial treatment and the receipt of rituximab have no influence on the development of long‐term fatigue.

show abstract

“…Comorbid conditions or other late effects and symptoms such as cardiovascular disease, pulmonary disease, overweight, sleep disturbance, hormonal changes, peripheral neuropathy, and persistent pain may also be contributory factors (3,13,14,16,17).…”

Section: Associated Factorsmentioning

confidence: 99%

“…Norwegian studies have shown that 25-35 % of long-term survivors of breast cancer, lymphoma and cervical cancer are affected by chronic fatigue (4,(13)(14)(15), and that 26 % and 13 % of hormone-naïve men reported chronic fatigue two years after radical radiotherapy and radical prostatectomy for prostate cancer, respectively (16). Recently it was demonstrated that the prevalence of chronic fatigue in Norwegian testicular cancer survivors increased from 15 % twelve years after treatment to 27 % seven years later (17).…”

Section: Measurement and Prevalencementioning

confidence: 99%

Kronisk tretthet hos voksne kreftoverlevere

Reinertsen¹,

Loge²,

Brekke³

et al. 2017

Tidsskriftet

Self Cite

View full text Add to dashboard Cite

Chronic fatigue is prevalent and associated with hormonal dysfunction in long-term non-Hodgkin lymphoma survivors treated with radiotherapy to the head and neck region

Cited by 18 publications

References 37 publications

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood

Chronic fatigue and associated factors among long-term survivors of cancers in young adulthood

Long‐term fatigue in survivors of non‐Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross‐sectional study

Kronisk tretthet hos voksne kreftoverlevere

Contact Info

Product

Resources

About